Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UB0316
- Development stage
- Unknown
- Lead developer
- Unique Biotech
- Modality
- Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
UB0316 is a multi-strain probiotic formulation designed to improve glycemic control and support weight management, particularly in patients with type 2 diabetes mellitus. The formulation contains the following strains at 5 billion CFU each per dose: *Lactobacillus salivarius* UBLS22, *Lactobacillus casei* UBLC42, *Lactobacillus plantarum* UBLP40, *Lactobacillus acidophilus* UBLA34, *Bifidobacterium breve* UBBr01, and *Bacillus coagulans* Unique IS2. It also includes 100 mg of fructo-oligosaccharides as a prebiotic component[2]. Clinical studies have shown that supplementation with UB0316 significantly reduces HbA1c levels and body weight compared to placebo in adults with type 2 diabetes on stable metformin therapy[1][2]. The mechanism of action is believed to involve modulation of gut microbiota composition and function, leading to improved metabolic parameters such as glycemic control. The product has demonstrated a favorable safety profile in clinical trials[1][2].
- Brand names
- UB0316UB-0316UB 0316
- Other names
- UB0316UB-0316UB 0316multi-strain probiotic formulation (UB0316)
Beyond the preview
Go deeper on UB0316.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UB0316.